- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06349408
IBI3001 hos deltagare med icke-opererbara, lokalt avancerade eller metastaserande solida tumörer
En fas 1/2-studie av IBI3001 på deltagare med icke-opererbara, lokalt avancerade eller metastaserande solida tumörer
This is a Phase 1 multicenter, multi-regional, open-label, first-in-human study of IBI3001 in participants with unresectable, locally advanced or metastatic solid tumors. The purpose of this study is to identify the MTD/RP2D of IBI3001, and to explore the preliminary efficacy of IBI3001.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
Studieorter
-
-
New South Wales
-
Wollongong, New South Wales, Australien, 2500
- Rekrytering
- Wollongong Hospital
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
-
South Australia
-
Adelaide, South Australia, Australien, 5000
- Rekrytering
- Cancer Research SA
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
-
-
-
California
-
Los Angeles, California, Förenta staterna, 90025
- Rekrytering
- START Center for Cancer Research
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
-
New Jersey
-
East Brunswick, New Jersey, Förenta staterna, 08816
- Rekrytering
- START Center for Cancer Research
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
-
Texas
-
Dallas, Texas, Förenta staterna, 75039
- Rekrytering
- NEXT Oncology
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
-
Virginia
-
Fairfax, Virginia, Förenta staterna, 22031
- Aktiv, inte rekryterande
- Virginia Cancer Specialists
-
-
-
-
Anhui
-
Hefei, Anhui, Kina, 230022
- Rekrytering
- The First Affiliated Hospital of Anhui Medical University
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 100021
- Rekrytering
- Cancer Hospital, Chinese Academy of Medical Sciences
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
Beijing, Beijing Municipality, Kina, 100853
- Rekrytering
- Chinese People's Liberation Army General Hospital
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
-
Fujian
-
Fuzhou, Fujian, Kina, 350014
- Rekrytering
- Fujian Cancer Hospital
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
Fuzhou, Fujian, Kina, 350005
- Rekrytering
- First Affiliated Hospital, Fujian Medical University
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
-
Guangxi
-
Nanning, Guangxi, Kina, 530021
- Rekrytering
- The Affiliated Tumor Hospital of Guangxi Medical University
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
-
Heilongjiang
-
Harbin, Heilongjiang, Kina, 150081
- Rekrytering
- Harbin Medical University Cancer Hospital
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
-
Henan
-
Anyang, Henan, Kina, 455100
- Rekrytering
- Anyang Cancer Hospital
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
Luoyang, Henan, Kina, 471003
- Rekrytering
- The First Affiliated Hospital of Henan University of Science and Technology
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
Zhengzhou, Henan, Kina, 450008
- Rekrytering
- Henan Cancer Hospital
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
Zhengzhou, Henan, Kina, 450052
- Rekrytering
- The First Affiliated Hospital of Zhengzhou University
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
-
Hubei
-
Wuhan, Hubei, Kina, 430022
- Rekrytering
- Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
-
Hunan
-
Changsha, Hunan, Kina, 410008
- Rekrytering
- Xiangya Hospital, Central South University
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
-
Jiangsu
-
Nanjing, Jiangsu, Kina, 210008
- Rekrytering
- Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
Nanjing, Jiangsu, Kina, 210029
- Rekrytering
- Jiangsu Province Hospital (The First Affiliated Hospital of Nanjing Medical University)
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
-
Jiangxi
-
Nanchang, Jiangxi, Kina, 330029
- Rekrytering
- Jiangxi Cancer Hospital
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina, 200120
- Rekrytering
- Shanghai East Hospital, Tongji University School of Medicine
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
-
Sichuan
-
Chengdu, Sichuan, Kina, 610041
- Rekrytering
- West China Hospital, Sichuan University
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
Chengdu, Sichuan, Kina, 610041
- Rekrytering
- Sichuan Cancer Hospital & Institute
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
-
Zhejiang
-
Hangzhou, Zhejiang, Kina, 310022
- Rekrytering
- Zhejiang Cancer Hospital
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
Hangzhou, Zhejiang, Kina, 310003
- Rekrytering
- The First Affiliated Hospital, Zhejiang University School of Medicine
-
Kontakt:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Key Inclusion Criteria:
- Male or female participants ≥ 18 years old;
- Has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1;
- Has an anticipated life expectancy of ≥ 12 weeks;
- Adequate bone marrow and organ function:
- At least 1 evaluable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. for dose escalation , and 1 measurable lesion for dose expansion.
- Has a documented (histologically- or cytologically-proven), unresectable, locally advanced or metastatic solid tumor that is refractory to or intolerable with standard treatment, or for which no standard treatment is available; participants who refuse standard therapy, or are able to suspend standard therapy without major risks.
Key Exclusion Criteria:
- Progressed or refractory to an ADC that consists of an Exatecan derivative that is a topoisomerase I inhibitor or intolerable with an ADC that consists of Exatecan;
- Plan to receive other antitumor therapy during the study excluding palliative radiotherapy for the purpose of symptom (like pain) relief that must also not have an impact on tumor assessment throughout the study;
- Pyloric obstruction and/or persistent recurrent vomiting (≥ 3 times in 24 hours);
- Gastrointestinal perforation and/or fistula within 6 months prior to first administration of the study drug, and not recovered after surgical treatment;
- Known symptomatic central nervous system (CNS) metastases.
- History of pneumonia requiring corticosteroids therapy, or history of clinically significant lung diseases; Uncontrolled diseases;
- History of endotracheal or gastrointestinal stent implantation;
- Ascites, pleural effusion, or pericardial effusion with symptoms and requiring intervention;
- Esophageal or gastric varices requiring immediate intervention;
- Not eligible to participate in this study at the discretion of the investigator;
- Do not have adequate treatment washout period before study drug administration. -
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Open-label: IBI3001 monoterapi
|
The provisional dose levels are planned to be evaluated, but it is possible for additional and/or intermediate dose levels to be added during the study. IBI3001 is proposed to be administered by intravenous infusion (IV) |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Number of subjects with adverse events
Tidsram: 24 months
|
Occurrence and severity of adverse events (AEs), with severity determined by NCI CTCAE v5.0 criteria |
24 months
|
|
Number of subjects with clinically significant changes in physical examination results
Tidsram: 24 months
|
Clinically significant abnormal physical examination findings reported by the investigator. |
24 months
|
|
Number of subjects with clinically significant changes in vital signs
Tidsram: 24 months
|
Vital signs including body temperature, pulse, respiratory rate, SpO2 and blood pressure |
24 months
|
|
MTD or RP2D of IBI3001 Number of subjects with dose-limiting toxicities (DLTs)
Tidsram: 24 months
|
Dose limiting toxicity (DLT) to establish MTD or RP2D |
24 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Plasma concentration (Cmax) of IBI3001
Tidsram: 24 months
|
Plasma concentration of IBI3001 for single and multiple doses. |
24 months
|
|
Area under the curve (AUC) of IBI3001
Tidsram: 24 months
|
AUC of IBI3001 for single and multiple doses |
24 months
|
|
Time to maximum concentration (Tmax) of IBI3001
Tidsram: 24 months
|
Tmax of IBI3001 for single and multiple doses. |
24 months
|
|
Clearance (CL) of IBI3001
Tidsram: 24 months
|
Clearance of IBI3001 from the plasma |
24 months
|
|
Volume of distribution (V) of IBI3001
Tidsram: 24 months
|
Apparent volume of distribution of IBI3001 |
24 months
|
|
Half-life (T1/2) of IBI3001
Tidsram: 24 months
|
T1/2 of IBI3001 for single and multiple doses |
24 months
|
|
Immunogenicity of IBI3001
Tidsram: 24 months
|
Incidence of anti-drug (IBI3001) antibody |
24 months
|
|
Objective response rate (ORR)
Tidsram: 24 months
|
ORR as evaluated per the RECIST v1.1 criteria |
24 months
|
|
Duration of response (DoR)
Tidsram: 24 months
|
DoR as evaluated per the RECIST v1.1 criteria |
24 months
|
|
Disease control rate (DCR)
Tidsram: 24 months
|
DCR as evaluated per the RECIST v1.1 criteria |
24 months
|
|
Time to response (TTR)
Tidsram: 24 months
|
TTR as evaluated per the RECIST v1.1 criteria |
24 months
|
|
Progression free survival (PFS)
Tidsram: 24 months
|
PFS as evaluated per the RECIST v1.1 criteria |
24 months
|
|
Overall survival (OS)
Tidsram: 24 months
|
Overall survival. |
24 months
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- CIBI3001A101
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .